Original strain - His-tagged RBD Protein

Original | RDB-His 

ABOUT

SARS-CoV-2 Spike RBD with C-terminal His tag

Protein description

The SARS-CoV-2 (2019-nCoV) Spike RBD (receptor binding domain) has been identified as the key viral element allowing the virus docking to the target cells. RDB is recognized by the ACE2 surface membrane receptor [1-3]. RBD is a candidate for subunit prophylactic vaccines against SARS-CoVs [4, 5]. RBD is also at the center of therapeutic approaches, such as the development and testing of small peptide inhibitors or soluble ACE2 to block the SARS-CoV-2 entry into target cells [6].
Spike-RBD-His was generated by fusing the C-terminus of SARS-CoV-2 Spike RBD [R319-F541] to a poly-histidine sequence (6 x His).
The SARS-CoV-2 viral sequence used is from the Wuhan-Hu-1 (D614) isolate.
This protein has been produced in CHO cells and purified by affinity chromatography (See Details and Specifications for more information).

Applications

  • Vaccination studies: using combinations of Spike protein antigens and adjuvants
  • Antibody screening: finding anti-Spike antibodies that can neutralize the SARS-CoV-2 infection
  • Inhibitor screening: finding small molecules, or antibodies able to block the SARS-CoV-2 RBD interaction with the ACE2 receptor
  • ACE2 cellular expression screening: in primary isolated cells or transfected cells

Quality control

 

Learn more on SARS-CoV-2 Learn more about SARS-CoV-2 infection cycle, immune responses, and potential therapeutics.

 

References

1. Li F., 2016. Structure, function, and evolution of coronavirus spike proteins. Annu. Rev. Virol. 3:237-261.
2. Li F. et al., 2005. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 309:1864-1868.
3. Walls A.C. et al., 2020. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 181(2):281-292.e6.
4. Wang N. et al., 2020. Subunit vaccines against emerging pathogenic human coronaviruses. Front. Microbiol. 11:298. DOI: 10.3389/fmicb.2020.00298.
5. Padron-Regalado E., 2020. Vaccines for SARS-CoV-2: Lessons from other coronavirus strains. Infect. Dis. Ther. DOI: 10.1007/s40121-020-00300-x.
6. Monteil V.et al., 2020. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 181:1-9.

All InvivoGen products are for internal research use only, and not for human or veterinary use.

SPECIFICATIONS

Specifications

Source
CHO cells
Accession sequence

YP_009724390

Protein size
234 a.a. (secreted form)
Tag
His, C-ter
Purity
>95% (SDS-PAGE)
Formulation buffer

Sodium phosphate buffer, glycine, saccharose, and stabilizing agents

Appearance (form)
Lyophilized
Reconstitution buffer
Endotoxin-free water (provided)
Endotoxin

Negative (tested using EndotoxDetect™ assay)

Tested applications

Cellular assays, ELISA

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Spike-RBD-His
  • Cat code: 
    his-sars2-rbd
  • Quantity: 
    50 µg
Includes:

1.5 ml of endotoxin-free water

Shipping & Storage

  • Shipping method:  Room temperature
  • Storage:

    • -20°C

    Caution:

    • Avoid repeated freeze-thaw cycles

DOCUMENTS

Documents

Spike-RBD-His

Technical Data Sheet

Validation Data Sheet

Plasmid Sequence

Safety Data Sheet

Certificate of analysis

Need a CoA ?

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?